| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 3.4% stake in Organogenesis Holdings Inc. |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Organogenesis Holdings Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/09/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
SC 13G
| Soleus Capital Master Fund, L.P. reports a 5.1% stake in Organogenesis Holdings Inc. |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/29/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/15/2022 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events Interactive Data |
| 03/01/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/18/2022 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors CANTON, Mass., February 17, 2022 — Organogenesis Holdings Inc. , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Michael J. Driscoll, Ed.D. to the Company's Board of Directors, effective February 15, 2022. Dr. Driscoll will serve as an independent director of the Company and member of the Audit Committee and the Nominating Committee of the Board. “I am pleased to welcome Dr. Driscoll to our Board of Directors following a 28-year career in the financial services industry, as well as 10 years in academia as a business school professor and dean.”..." |
|
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/04/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/30/2021 |
SC 13D/A
| Ades Alan A. reports a 20.5% stake in Organogenesis Holdings Inc. |
| 12/30/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
|